The Clinical Impact of Vehicle Technology Using a Patented Formulation of Benzoyl Peroxide 5%/Clindamycin 1% Gel Containing Dimethicone and Glycerin in Combination with Topical Retinoids and Sunscreens

February 2006 | Volume 5 | Issue 2 | Original Article | 160 | Copyright © February 2006

James Q. Del Rosso DO FAOCD, Emil Tanghetti MD

A major challenge encountered in clinical practice in patients with acne vulgaris is irritation related to topical medications used for treatment. Advances in vehicle technology have improved formulations containing active ingredients known to produce irritation in some patients, such as benzoyl peroxide (BP) and topical retinoids. Clinical studies, including combination therapy studies have demonstrated that certain additives, such as silicates and specific humectants, reduce irritation by maintaining barrier integrity. A patented gel formulation of BP 5%/clindamycin phosphate 1% (clindamycin) containing dimethicone and glycerin has been studied both as a monotherapy and in combination with topical retinoid use. This article evaluates specific vehicle additives included in this gel formulation and explains their role in reducing irritation. Data from clinical trials utilizing this technology in acne management are also reviewed.